Cases of giardiasis, an intestinal infection that causes diarrhea, bloating and gas, have reached their highest level in ...

The company's TEV-408 antibody met its primary endpoint in a 50-patient trial and reduced intestinal damage, inflammation and ...

A systemic antifungal medicine reduced intestinal Candida and was associated with improved gut health in a small study of ...

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — ...

Teva's investigational anti-interleukin-15 monoclonal antibody (mAb) has met its primary endpoint in a Phase IIa trial in celiac disease.

Teva Pharmaceutical Industries Ltd. TEVA on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical ...

Teva's TEV '408 shows promise in preventing gluten-induced intestinal damage in celiac disease, with positive Phase 2a study ...

Teva Pharmaceutical (TEVA) stock gains as the company succeeds in a mid-stage trial for its celiac disease therapy developed ...

Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related ...

The two gut conditions share almost every symptom, but a specific cluster can point one way rather than the other.

Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of ...

Disabled fructose processing (bottom row) led to shorter lacteals, tiny lymphatic vessels in the villi, which give the ...